Subcutaneous · Activin receptor type IIA / IIB targeting
JMT206
2 trials in this molecule. Source: ClinicalTrials.gov, as of November 5, 2026.
Trials
2
Ongoing
2
Recruiting
2
Completed
0
Sites
2
Countries
1
Endpoints
2
Composite endpoints
0
Distinct sites and countries across this molecule's trials. A site running several of its trials counts once, matching the map.
Where the program stands
Trials by phase
Phase 1
2
Trials by status
Recruiting
2
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Safety / tolerability / PK
2
Top 20 metrics across this asset's endpoints
Programs for this asset
Every trial for this molecule, with the same search, filters, and sort as the Trials tab.
⌘K
2 of 2
| Asset / Population | Eligibility highlight | Evidence | ||||||
|---|---|---|---|---|---|---|---|---|
| NCT07840729Evaluate the Safety and Tolerability of Multiple Doses of JMT206 Injection in Obese Participants | JMT206, Semaglutide | BMI ≥30 | Ph 1 | Recruiting | 1 | Feb 2027 | - | |
| NCT07419698Evaluate the Safety, Tolerability, PK, and PD of JMT206 Injection in Healthy Participants | JMT206 Healthy volunteers | BMI 19-28 | Ph 1 | Recruiting | 1 | Sep 2026 | - |
Showing 1-2 of 2 trials